Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension

NCT06429579 | Recruiting DMC

• 1 other identifier: NCRC2024001
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multi-center, perspective, and exploratory study aimed at evaluating the 3-years clinical outcome of Potts-shunt procedure for pediatric patients with severe pulmonary artery hypertension (PAH). The included criteria are as followed: 1)6 months \< age ≤ 18 years; 2) ESC 2022 Group I PAH; 3) Have received standardized drug therapy for at least 6-9 months and still remain at intermediate to high/high-risk status of the criteria of ESC2022; 4) Presenting with significant clinical manifestations (i.e., progressive symptoms/syncope history/growth and development restriction, etc); 5) Informed consent form signed by the patient and their guardian. The excluded criteria are as followed: 1) ESC 2022 Group II-V PAH; 2) Poor right ventricular function: RVEF \< 25% or RVFAC \< 20%; 3) Deteriorated general condition: requiring ICU resuscitation or ECMO assistance; 4) Pulmonary artery pressure/main arterial pressure ratio \< 0.7; 5) Six-minute walk distance \< 150 meters (only applicable to patients aged 8 and above); 6) No significant improvement in RVEF under triple drug therapy. All of the pediatric patients with severe PAH who attend to pediatric cardiac outpatient clinic and meet the designed included criteria and excluded criteria will be enrolled in this study. All of the participants will be divided into two groups (Potts-shunt combined with conventional drug therapy group and only conventional drug therapy group) according to their individual health status (i.e., some contraindications of surgery) and their (or their parents') aspiration for Potts-shunts procedure. Follow-up is designed (eight-times follow-up) at the time of Potts-shunt procedure, post-operative ICU period, one month, three months, six months, one year, two years, and three years after Potts-shunt procedure or the rejection of Potts-shunt procedure. The items of follow-up include state of survival, whether or not have the lung transplantation (LTx), clinical manifestation, laboratory examination, function of right ventricle (detected by echocardiogram and cardiac magnetic resonance imaging), and the pulmonary circulation pressure (detected by right heart catheterization or Swan-Ganz catheterization). Primary outcome is the incidence rates of death or LTx three-years after Potts-shunt. Secondary outcomes are as followed: 1) Number and incidence rate of postoperative complications in patients undergoing Potts-shunt procedure; 2) Three-year WHO cardiac functional and 6-minute walk distance after Potts-shunt procedure; 3) the NT-ProBNP levels three-years after Potts-shunt procedure; 4) Right ventricular function on echocardiography three years after Potts-shunt procedure; 5) Right ventricular function on cardiac magnetic resonance imaging three years after Potts-shunt procedure; 6) Pulmonary circulation pressure measured by right heart catheterization or Swan-Ganz catheterization three years after Potts-shunt procedure; 7) Three-year mortality or LTx incidence rates after only conventional drug therapy.

Conditions

Pulmonary Artery Hypertension

Outcome Measures

Primary Outcomes (1)

• Mortality or Lung transplantation

  The incidence rates of death or lung transplantation 3 years after Potts-shunt, accessed by in-patient, out-patient, or telephone follow-up

  From the date of enrollment until the date of dear from any cause or lung transplantation, which ever came first, accessed up to 3 years

Secondary Outcomes (8)

• Number and incidence rate of postoperative complications in patients undergoing Potts-shunt procedure

  From the date of enrollment to the date of any postoperative complications, whichever came first, accessed up to 3 years

• World Health Organization functional class (WHO-FC) after Potts-shunt procedure

  From the date of enrollment to the date of every view-point, assessed up to 3 years

• NT-ProBNP levels after Potts-shunt procedure

  From the date of enrollment to the date of every view-point, assessed up to 3 years

• Right ventricular function on cardiac magnetic resonance imaging after Potts-shunt procedure

  From the date of enrollment to the date of every view-point, assessed up to 3 years

• Right ventricular function on echocardiography after Potts-shunt procedure

  From the date of enrollment to the date of every view-point, assessed up to 3 years

Study Arms (2)

Potts-shunt combined with conventional drug therapy group

EXPERIMENTAL

The comprehensive therapy included Potts-shunt procedure and conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)

Procedure: Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy

Only conventional drug therapy group

ACTIVE COMPARATOR

Only admitted with conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)

Drug: Only conventional drug therapy

Interventions

Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy PROCEDURE

Potts-shunt procedure is the surgery that connect the descending aorta and the left/main pulmonary artery by direct anastomosis, a Gore-tex tube or a Gore-tex tube with flap.

Potts-shunt combined with conventional drug therapy group

Only conventional drug therapy DRUG

Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)

Only conventional drug therapy group

Eligibility Criteria

• Age: 6 Months - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• months \&lt; age ≤ 18 years;
• ESC 2022 Group I PAH;
• Have received standardized drug therapy for at least 6-9 months and still remain at intermediate to high/high-risk status of the criteria of ESC2022;
• Presenting with significant clinical manifestations (i.e., progressive symptoms/syncope history/growth and development restriction, etc);
• Informed consent form signed by the patient and their guardian.

You may not qualify if:

• ESC 2022 Group II-V PAH;
• Poor right ventricular function: RVEF \&lt; 25% or RVFAC \&lt; 20%;
• Deteriorated general condition: requiring ICU resuscitation or ECMO assistance;
• Pulmonary artery pressure/main arterial pressure ratio \&lt; 0.7;
• Six-minute walk distance \&lt; 150 meters (only applicable to patients aged 8 and above);
• No significant improvement in RVEF under triple drug therapy.

Sponsors & Collaborators

• China National Center for Cardiovascular Diseases: lead

Study Sites (1)

Pediatric cardic surgical center, Fuwai Hospital

Beijing, Beijing Municipality, 100037, China

RECRUITING

MeSH Terms

Conditions

Familial Primary Pulmonary Hypertension

Condition Hierarchy (Ancestors)

Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Shoujun Li, MD

CONTACT

+8613501071589; drlishoujunfw@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 5, 2024
• First Posted: May 28, 2024
• Study Start: April 23, 2024
• Primary Completion (Estimated): April 23, 2029
• Study Completion (Estimated): April 23, 2029
• Last Updated: May 28, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)